T
TCBP
vs
S&P 500
S&P 500
Over the past 12 months, TCBP has underperformed S&P 500, delivering a return of -95% compared to the S&P 500's +14% growth.
Stocks Performance
TCBP vs S&P 500
Performance Gap
TCBP vs S&P 500
Performance By Year
TCBP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TC BioPharm Ltd
Glance View
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The firm is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The firm's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf allogeneic gamma delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. The firm also provides in-house and partner programs at the pre-clinical stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.